EFFECTS - The Salt Lake Tribune http://www.sltrib.com/feeds/topics/EFFECTS News from The Salt Lake Tribune en-us webmaster@sltrib.com (Webmaster) Merck to pay $3.85 billion for hepatitis C drug developer http://www.sltrib.com/sltrib/money/58046893-79/merck-hepatitis-drug-patients.html.csp <div class="hnews hentry item"> <h4><a class="url entry-title" href="http://www.sltrib.com/sltrib/money/58046893-79/merck-hepatitis-drug-patients.html.csp">Merck to pay $3.85 billion for hepatitis C drug developer</a></h4> <span class="author vcard"><span class="fn">By LINDA A. JOHNSON</span></span> <span class="source-org vcard"><span class="org fn"> The Associated Press</span></span> <h5><span class="updated" title="2014-06-09T14:34:02.428-06:00">Updated Jun 9, 2014 02:34PM MDT</span></h5> <div class ="entry-content">Trenton, N.J. • Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck’s experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions. The price for the deal announced Monday — a per-share bid more than triple Friday’s closing price for Cambridge, Massachusetts-based Idenix — seems high. However, the latest hepatitis...</div> <h5><a rel="item-license" href="#license-580468932014-06-09T14:34:02.428-06:00" id="#license-2014-06-09T14:34:02.428-06:00"> Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.</a></h5> </div> 58046893@www.sltrib.com Mon, 09 Jun 2014 14:34:02 MDT